Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 8/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3697142 | 1.00 | SLC2A1 (0.47) | SLC2A1KCNH2THRBKDM4EMEN1 | |
| SCHEMBL5317247 | 0.89 | MTNR1A (0.36) | SLC2A1KCNH2ALDH1A1 | |
| SCHEMBL5317252 | 0.89 | MTNR1A (0.36) | SLC2A1KCNH2ALDH1A1 | |
| SCHEMBL3688107 | 0.88 | KCNH2 (0.47) | SLC2A1KCNH2THRBKDM4EMEN1 | |
| SCHEMBL3694553 | 0.88 | KCNH2 (0.47) | SLC2A1KCNH2THRBKDM4EMEN1 | |
| SCHEMBL5728191 | 0.87 | KCNH2 (0.61) | SLC2A1KCNH2 | |
| SCHEMBL5430646 | 0.85 | KCNH2 (0.38) | SLC2A1KCNH2ALDH1A1 | |
| SCHEMBL5430642 | 0.85 | KCNH2 (0.38) | SLC2A1KCNH2ALDH1A1 | |
| SCHEMBL5432717 | 0.84 | SLC2A1 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL5432710 | 0.84 | SLC2A1 (0.46) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239260-A1 | Novel compounds with antibacterial activity | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MORPHOCHEM AG | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040949-A1 | Novel compounds with antibacterial activity | MRPL21, Q6ZSR9, MRPL19 | SLC2A1 4070/4885KCNH2 2411/4885THRB 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.